<DOC>
	<DOCNO>NCT00985114</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy second generation EndoBarrier Liner compare study diet treat Subjects Type 2 Diabetes . This randomize , control study enroll approximately 70 Subjects Type 2 Diabetes . Randomization one one approximately 35 EndoBarrier device Subjects approximately 35 study diet Subjects . Subjects randomized diet Subjects offer EndoBarrier device 12 month study investigator 's discretion treatment device subject indicate adequate efficacy . This study conduct three ( 3 ) investigational site . The primary efficacy endpoint : - Assessment percent ( % ) Subjects achieve ≥ 0.5 % reduction HbA1C 24 week last visit baseline two group . Secondary endpoint : - Percent ( % ) Subjects achieve HbA1C 7.0 % low week 24 last visit baseline . - Percent ( % ) Subjects diabetic medication ( ) dosage decrease discontinue week 24 last visit baseline . - Percent ( % ) Subjects achieve decrease post-prandial excursion evidence challenge standardize meal tolerance test ( MTT ) week 24 last visit baseline . - Assessment absolute weight loss ( Kg ) week 24 last visit baseline . - Percent ( % ) Subjects maintain HbA1c low baseline assessment 12 month . - Compare physical component summary ( PCS ) , mental component summary ( MCS ) quality adjust life year ( QALYs ) via analysis SF-36v2 QOL .</brief_summary>
	<brief_title>Safety Efficacy Study EndoBarrier Subjects With Type II Diabetes Obesity</brief_title>
	<detailed_description>Utilization EndoBarrier Gastrointestinal Liner obese subject T2DM demonstrate acceptable safety profile clinically significant improvement glycemic control body weight compare similar diet control group subject .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Age &gt; 18 year &lt; 65 year Male Female Subjects Type 2 Diabetes treat ≤10 year BMI &gt; 30 &lt; 50 Subjects HbA1c level &gt; 7.5 ≤ 10.0 % Subjects take combination metformin sulfonylureas and/or insulin ( premixed long short acting insulin , ie . NovoMix 30 ) Patients willing comply study requirement Patients sign informed consent form Subjects take oral medication control diabetes sulfonylureas metformin Subjects diagnose Type 1 Diabetes Mellitus history ketoacidosis Subjects insulin &gt; 10 year Subjects require insulin &gt; 70 unit per day Subjects premixed insulin ( ie . NovoMix 30 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Type II Diabetes</keyword>
	<keyword>Obesity</keyword>
</DOC>